Loading
CAPTEM (capecitabine plus temozolomide) is an all-oral chemotherapy pair that shrinks pancreatic neuroendocrine tumours in about a third of patients.
ECOG-ACRIN E2211 (2018-2023): PFS 22.7 vs 14.4 months and higher response rate for CAPTEM versus temozolomide alone in pancreatic NETs; OS did not differ at final analysis. Used when tumour shrinkage is needed (bulky or symptomatic disease) and in grade 3 NETs. MGMT deficiency may predict response.
Fluoropyrimidine plus alkylating agent; capecitabine depletes MGMT, sensitising to temozolomide.
1.Capecitabine + temozolomide (CAPTEM) slips into a pocket on its target.
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3-4) | - | 13% |
| Thrombocytopenia (grade 3-4) | - | 15% |
| Fatigue | 50% | - |
E2211. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Capecitabine + temozolomide" OR ABSTRACT:"Capecitabine + temozolomide" OR TITLE:"CAPTEM" OR ABSTRACT:"CAPTEM") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Capecitabine + temozolomide (CAPTEM), not a curated reading list.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Extrapulmonary neuroendocrine carcinoma, Pancreatic neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lung neuroendocrine tumours (typical and atypical carcinoid), Pancreatic neuroendocrine tumours, Neuroendocrine tumours.
Shares Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE, Grade 3 well-differentiated neuroendocrine tumour, Pancreatic neuroendocrine tumours, Neuroendocrine tumours.